Alginate controls heartburn in patients with erosive and nonerosive reflux disease
Authors:
- Edoardo SavarinoESEdoardo Savarino
- Nicola De BortoliNicola De Bortoli
- Patrizia ZentilinPZPatrizia Zentilin
- Irene MartinucciIMIrene Martinucci
- Luca BruzzoneLBLuca Bruzzone
- Manuele FurnariMFManuele Furnari
- Santino MarchiSMSantino Marchi
- Vincenzo SavarinoVSVincenzo Savarino
Open Access
- 1 January 2012
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 18 (32) , 4371-8
Abstract
To evaluate the effect of a novel alginate-based compound, Faringel, in modifying reflux characteristics and controlling symptoms. In this prospective, open-label study, 40 patients reporting heartburn and regurgitation with proven reflux disease (i.e., positive impedance-pH test/evidence of erosive esophagitis at upper endoscopy) underwent 2 h impedance-pH testing after eating a refluxogenic meal. They were studied for 1 h under basal conditions and 1 h after taking 10 mL Faringel. In both sessions, measurements were obtained in right lateral and supine decubitus positions. Patients also completed a validated questionnaire consisting of a 2-item 5-point (0-4) Likert scale and a 10-cm visual analogue scale (VAS) in order to evaluate the efficacy of Faringel in symptom relief. Tolerability of the treatment was assessed using a 6-point Likert scale ranging from very good (1) to very poor (6). Faringel decreased significantly (P < 0.001), in both the right lateral and supine decubitus positions, esophageal acid exposure time [median 10 (25th-75th percentil 6-16) vs 5.8 (4-10) and 16 (11-19) vs 7.5 (5-11), respectively] and acid refluxes [5 (3-8) vs 1 (1-1) and 6 (4-8) vs 2 (1-2), respectively], but increased significantly (P < 0.01) the number of nonacid reflux events compared with baseline [2 (1-3) vs 3 (2-5) and 3 (2-4) vs 6 (3-8), respectively]. Percentage of proximal migration decreased in both decubitus positions (60% vs 32% and 64% vs 35%, respectively; P < 0.001). Faringel was significantly effective in controlling heartburn, based on both the Likert scale [3.1 (range 1-4) vs 0.9 (0-2); P < 0.001] and VAS score [7.1 (3-9.8) vs 2 (0.1-4.8); P < 0.001], but it had less success against regurgitation, based on both the Likert scale [2.6 (1-4) vs 2.2 (1-4); P = not significant (NS)] and VAS score [5.6 (2-9.6) vs 3.9 (1-8.8); P = NS]. Overall, the tolerability of Faringel was very good 5 (2-6), with only two patients reporting modest adverse events (i.e., nausea and bloating). Our findings demonstrate that Faringel is well-tolerated and effective in reducing heartburn by modifying esophageal acid exposure time, number of acid refluxes and their proximal migration.Keywords
This publication has 55 references indexed in Scilit:
- Wound Healing and Anti-Inflammatory Effect in Animal Models ofCalendula officinalisL. Growing in BrazilEvidence-Based Complementary and Alternative Medicine, 2012
- Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patientsJournal of Gastroenterology, 2011
- An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial ‘acid pocket’ in symptomatic GERD patientsAlimentary Pharmacology & Therapeutics, 2011
- Proximal oesophagus: the added value in understanding GORD symptomsNeurogastroenterology & Motility, 2009
- A Randomized, Double-Blind, Placebo-Controlled Trial of Oral Matricaria recutita (Chamomile) Extract Therapy for Generalized Anxiety DisorderJournal of Clinical Psychopharmacology, 2009
- Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux diseaseGut, 2009
- A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux SymptomsDigestive Diseases and Sciences, 2006
- Antacids RevisitedDrugs, 1999
- Alginic acid decreases postprandial upright gastroesophageal refluxDigestive Diseases and Sciences, 1992
- Evaluation of elevation of the head of the bed, bethanechol, and antacid foam tablets on gastroesophageal refluxDigestive Diseases and Sciences, 1981